Stem cell secretome attenuates acute rejection in rat lung allotransplant.


Journal

Interactive cardiovascular and thoracic surgery
ISSN: 1569-9285
Titre abrégé: Interact Cardiovasc Thorac Surg
Pays: England
ID NLM: 101158399

Informations de publication

Date de publication:
01 05 2019
Historique:
received: 24 07 2018
revised: 06 09 2018
accepted: 23 09 2018
pubmed: 7 12 2018
medline: 14 1 2020
entrez: 4 12 2018
Statut: ppublish

Résumé

Stem cells secrete significant amounts of bioactive factors in their secretome that can be immunosuppressive. We studied the effect of the secretome obtained from bone marrow-derived mesenchymal stem cells (BMSC-sec) in combination with cyclosporine A following acute rejection of lung allografts in the rat. Lung allotransplants were performed from male Brown Norway donor rats to recipient male Fisher 344 rats. Rat BMSC-sec was introduced intratracheally in the recipient every day after the transplant until the day the animal was sacrificed. Group A (n = 5) received control medium and cyclosporine A (2.5 mg/kg body weight intraperitoneally) for 5 days post-transplant and group B (n = 5) received BMSC-sec and cyclosporine A. Blood gas analysis was performed to assess graft function at day 5 only from the graft, and the tissue was sampled for measurement of the wet/dry ratio and histological grading of rejection. All control animals (group A) showed severe signs of rejection. At day 5 grafts in group B showed improved gas exchange (i.e. mean PaO2 mmHg 237.9 ± 130 mmHg vs 24.9 ± 7.8 mmHg in group A). Histological examination according to the International Society of Heart and Lung Transplantation (ISHLT) revealed moderate to severe rejection in all animals in group A (III B) and a significant improvement in group B (I-IIA). The wet/dry ratio was also reduced in group B to 6.19 ± 0.6 compared to 9.36 ± 2 in group A. Furthermore, in vitro T-cell proliferation was reduced after treatment with BMSC-sec for CD 3 cells (69.55 ± 07 vs 73 ± 0.84), for CD 4 (24.95 ± 1.2 vs 27.75 ± 0.21) and for CD 8 cells (3.75 ± 0.2 vs 5.68 ± 0.02). The BMSC-sec is a promising novel cell-based therapeutic option for acute rejection in a rat lung allograft model.

Identifiants

pubmed: 30508108
pii: 5224541
doi: 10.1093/icvts/ivy306
doi:

Substances chimiques

Immunosuppressive Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

812-818

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Auteurs

Jarosław Pieróg (J)

Department of General Thoracic Surgery, University Hospital Bern, Bern, Switzerland.
Department of General Thoracic Surgery and Lung Transplantation, Pomeranian Medical University, Szczecin, Poland.
Department for Biomedical Research, University of Bern, Bern, Switzerland.

Kleanthis Fytianos (K)

Department for Biomedical Research, University of Bern, Bern, Switzerland.
Department of Pulmonary Medicine, University Hospital Bern, Bern, Switzerland.

Luca Tamò (L)

Department of General Thoracic Surgery, University Hospital Bern, Bern, Switzerland.
Department for Biomedical Research, University of Bern, Bern, Switzerland.
Graduate School, University of Bern, Bern, Switzerland.

Cedric Simillion (C)

Department for Biomedical Research, University of Bern, Bern, Switzerland.

Adriano Taddeo (A)

Department for Biomedical Research, University of Bern, Bern, Switzerland.

Gregor Kocher (G)

Department of General Thoracic Surgery, University Hospital Bern, Bern, Switzerland.
Department for Biomedical Research, University of Bern, Bern, Switzerland.

Mathias Gugger (M)

Promed AG, Freiburg, Freiburg Switzerland.

Tomasz Grodzki (T)

Department of General Thoracic Surgery and Lung Transplantation, Pomeranian Medical University, Szczecin, Poland.

Manfred Heller (M)

Department for Biomedical Research, University of Bern, Bern, Switzerland.

Fabian Blank (F)

Department for Biomedical Research, University of Bern, Bern, Switzerland.
Department of Pulmonary Medicine, University Hospital Bern, Bern, Switzerland.

Thomas Geiser (T)

Department for Biomedical Research, University of Bern, Bern, Switzerland.
Department of Pulmonary Medicine, University Hospital Bern, Bern, Switzerland.

Ralph A Schmid (RA)

Department of General Thoracic Surgery, University Hospital Bern, Bern, Switzerland.
Department for Biomedical Research, University of Bern, Bern, Switzerland.

Amiq Gazdhar (A)

Department for Biomedical Research, University of Bern, Bern, Switzerland.
Department of Pulmonary Medicine, University Hospital Bern, Bern, Switzerland.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH